EcoDrugPlus

Nicotinamide Phosphoribosyltransferase

Ensembl ID : ENSOTSG00005038228
Gene Symbol: NAMPT
3 Cross references
153 Possible Orthologues:

Nicotinamide Phosphoribosyltransferase

Ensembl ID : ENSOTSG00005029027
Gene Symbol: NAMPT
3 Cross references
153 Possible Orthologues:

Nicotinamide Phosphoribosyltransferase

Ensembl ID : ENSOTSG00005016560
Gene Symbol: NAMPT
1 Cross references
220 Possible Orthologues:

Nicotinamide Phosphoribosyltransferase

Ensembl ID : ENSOTSG00005027911
Gene Symbol: NAMPT
1 Cross references
217 Possible Orthologues:

Nitric Oxide Synthase 2

Ensembl ID : ENSOTSG00005042591
Gene Symbol: NOS2
1 Cross references
160 Possible Orthologues:

Nitric Oxide Synthase, Inducible-Like

Ensembl ID : ENSOTSG00005028330
Gene Symbol: LOC112266155
2 Cross references
159 Possible Orthologues:

Notch Receptor 1b

Ensembl ID : ENSOTSG00005009635
Gene Symbol: NOTCH1B
1 Cross references
194 Possible Orthologues:

Notch Receptor 1b

Ensembl ID : ENSOTSG00005047988
Gene Symbol: NOTCH1B
1 Cross references
192 Possible Orthologues:

Notch Receptor 3

Ensembl ID : ENSOTSG00005040500
Gene Symbol: NOTCH3
1 Cross references
196 Possible Orthologues:

Notch Receptor 3

Ensembl ID : ENSOTSG00005004378
Gene Symbol: NOTCH3
1 Cross references
196 Possible Orthologues:

Nuclear Factor Erythroid 2-Related Factor 2-Like

Ensembl ID : ENSOTSG00005036933
Gene Symbol: LOC112219800
3 Cross references
199 Possible Orthologues:

Nuclear Factor Erythroid 2-Related Factor 2-Like

Ensembl ID : ENSOTSG00005030963
Gene Symbol: LOC112220178
3 Cross references
199 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).